Try our Advanced Search for more refined results

JANSSEN PHARMACEUTICALS, INC. et al v. TEVA PHARMACEUTICALS USA, INC. et al

  1. December 18, 2024

    J&J Unit Beats Schizophrenia Drug IP Challenge On Remand

    Teva Pharmaceuticals USA Inc. has failed to invalidate claims in a patent for a Johnson & Johnson unit's blockbuster schizophrenia medicine, according to a New Jersey federal judge who rejected the generic-drug maker's assertions that the formula was obvious.

  2. August 05, 2024

    J&J, Generics Spar In Remand On Schizophrenia Drug Patent

    Following a Federal Circuit ruling that gave generics makers Teva and Viatris a new shot at trying to invalidate the last remaining patent on Johnson & Johnson's blockbuster schizophrenia drug Invega Sustenna, the parties are sparring over the impact of the appeals court's decision.

  3. April 01, 2024

    Fed. Circ. Revives Challenges To J&J Schizophrenia Drug

    A Federal Circuit panel on Monday gave generics-makers Teva Pharmaceuticals USA Inc. and Viatris Inc. a new chance to prove that a patent on Johnson & Johnson's blockbuster schizophrenia drug Invega Sustenna is invalid, saying a lower court used an "erroneously rigid" analysis when rejecting their challenge.

  4. June 10, 2021

    Teva Gets Judge To Nix Drug IP Inventorship Correction Order

    A New Jersey federal judge took the unusual step of reversing an order telling the U.S. Patent and Trademark Office to add two inventors to a Janssen Pharmaceuticals Inc. patent after its rival Teva informed the court that it had never consented to the inventors' addition.

  5. January 18, 2018

    Janssen Sues Teva To Stop Generic Of Schizophrenia Drug

    A generic version of the schizophrenia drug Invega Sustenna that Teva Pharmaceuticals seeks to manufacture and sell would infringe the asserted claims of a patent covering the drug, Janssen Pharmaceuticals Inc. alleged Wednesday in New Jersey federal court.